𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent

✍ Scribed by M. Panisset; S. Gauthier; H. Moessler; M. Windisch; and The Cerebrolysin Study Group


Publisher
Springer
Year
2002
Tongue
English
Weight
103 KB
Volume
109
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


A double-blind, placebo-controlled singl
✍ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional de®cits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire

A randomized, double-blind, placebo-cont
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Randomized, placebo-controlled, double-b
✍ Andrea Martinuzzi; Alexandra Liava; Enrico Trevisi; Mara Frare; Caterina Tonon; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

## Abstract McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin‐converting enzyme (ACE) insertion (I)/deletion (D) haplotype—patients with the genotype associated with higher ACE activity show the most severe